MENLO PARK, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the...
Successful go-public transaction and over $475 million raised this year provides cash runway through multiple clinical inflection points ORKA-001 non-human primate (NHP) pharmacokinetic and in...
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -5.9 | -22.3273415326 | 26.425 | 27.4 | 19.57 | 247295 | 22.36448803 | CS |
4 | -9.955 | -32.6607611549 | 30.48 | 30.65 | 19.57 | 165450 | 25.3634865 | CS |
12 | -4.975 | -19.5098039216 | 25.5 | 31.13 | 19.57 | 106522 | 26.00645851 | CS |
26 | -4.975 | -19.5098039216 | 25.5 | 31.13 | 19.57 | 106522 | 26.00645851 | CS |
52 | -4.975 | -19.5098039216 | 25.5 | 31.13 | 19.57 | 106522 | 26.00645851 | CS |
156 | -4.975 | -19.5098039216 | 25.5 | 31.13 | 19.57 | 106522 | 26.00645851 | CS |
260 | -4.975 | -19.5098039216 | 25.5 | 31.13 | 19.57 | 106522 | 26.00645851 | CS |
Aucune Discussion Trouvée |
Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales